Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02148159 · ClinicalTrials.gov registry record · NA
Acupuncture for Unintentional Weight Loss and Anorexia With GI Cancer
A NA study, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT02148159: Completed NA study, sponsored by University of Florida.
NCT02148159 is a NA study that has completed, run by University of Florida. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02148159, a NA study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
Patients with cancer often experience appetite loss and weight loss unintentionally. Rapid weight loss negatively impact on physical functioning, quality of life, and overall survival. Patients will be randomly assigned into two groups. An intervention with acupuncture may slow down or stop the progression of cancer-related anorexia and weight loss.
Primary Outcome
Weight will be measured each visit (pounds).
Interventions
- DEVICE Cachexia Acupuncture-A (Peace Classic Needles® )
- DEVICE General Acupuncture-B (Peace Classic Needles®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-05 |
| Phase | NA |
What the finished NCT02148159 record still lists
NCT02148159 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Cachexia Acupuncture-A (Peace Classic Needles® ) is the first listed.
NCT02148159 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02148159 about?
NCT02148159 is a clinical study titled "Acupuncture for Unintentional Weight Loss and Anorexia With GI Cancer". Patients with cancer often experience appetite loss and weight loss unintentionally. Rapid weight loss negatively impact on physical functioning, quality of life, and overall survival. Patients will be randomly assigned into two groups. An intervention with acupuncture may slow down or stop the prog...
What is the current status of trial NCT02148159?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2014-10. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02148159?
The interventions under investigation include: Cachexia Acupuncture-A (Peace Classic Needles® ) (DEVICE), General Acupuncture-B (Peace Classic Needles®) (DEVICE).
Who is sponsoring clinical trial NCT02148159?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02148159's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia